Teva Pharmaceutical Industries Limited (TEVA) Stock: Price, Forecast & Analyst Target
Teva Pharmaceutical Industries Limited (TEVA) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $38.54 (-8.74%), as of the Nov 19, 2026 trading session; market cap $45.0B.
Educational signal · not a buy or sell recommendation · How to read this
Teva Pharmaceutical Industries Limited · TEVA · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic
Research dated 2026-09-12: Teva is a global medicine manufacturer whose revenue comes chiefly from products spanning generics, specialty drugs, biopharmaceuticals, and active pharmaceutical ingredients, with smaller distribution and licensing streams. Product growth and cash generation must overcome uneven reported profit and debt that stands far above available liquidity.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Teva Pharmaceutical Industries (TEVA)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, but a fragile balance sheet and a full valuation; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- Altman Z 0.94 · Piotroski F 7
- ROE 6.4% · ROA 1.3% · current ratio 0.95 · earnings yield 1.0% · free-cash-flow yield 2.4%
Holding back: balance-sheet strain
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 60 | Fair | |
| 61 | Fair | |
| 62 | Fair | |
| 62 | Fair | |
| 57 | Fair | |
| 57 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $38.54 | |
| Change on the day | -8.74% | |
| 52-week range | $24.01–$44.57 | |
| Market capitalisation | $45.0B | — |
| Price / earnings (trailing) | 94.71 | |
| Shares traded on the day | 10.34M | |
| Beta (volatility vs the S&P 500) | 0.84 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Teva Pharmaceutical Industries (TEVA): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Teva Pharmaceutical Industries (TEVA), and what does it report?
Short answer · as of
Calling Teva merely a generic-drug maker leaves out branded franchises such as AUSTEDO, AJOVY, and Copaxone, a broad respiratory and oncology portfolio, active pharmaceutical ingredients, and long-acting injectable development.
Research dated 2026-09-12.
Reported revenue is overwhelmingly product sales, supplemented by distribution services, licensing, and other activities, so demand reflects prescriptions, customer orders, portfolio pricing, and commercial partnerships rather than a royalty stream alone.
What do the latest results show for Teva Pharmaceutical Industries (TEVA)?
Research dated 2026-09-12.
The latest period delivered higher revenue and gross profit than the preceding period, yet operating profit contracted sharply and the net result swung to a loss. Revenue exceeded the consensus estimate while the reported earnings measure missed it, and operating cash flow recovered from an outflow even as profit conversion deteriorated.
Management expects operating expenses to normalize as transformation savings gain impact and continues to guide toward its stated gross-margin band. It has separately warned that AUSTEDO faces weaker purchasing patterns and a tougher pricing environment ahead of IRA implementation, making that product a specific pressure rather than evidence of portfolio-wide demand weakness.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $4.48B | $433M | $0.37 (diluted) |
| Q4 FY2025 | $4.71B | $480M | $0.41 (diluted) |
| Q1 FY2026 | $3.98B | $369M | $0.31 (diluted) |
| Q2 FY2026 | $4.14B | -$576M | -$0.49 (diluted) |
What are the financial strengths and risks for Teva Pharmaceutical Industries (TEVA)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Teva returned to annual profitability after a run of losses, and recent operating cash flow shows the business can generate substantial cash. That strength is irregular: cash flow has moved between outflows and strong inflows, while quarterly earnings have also shifted between profit and loss.
The cash balance sits near the upper end of its recent range and is concentrated in cash and short-term investments, but debt remains far larger. Positive trailing margins and a healthy free-cash-flow yield coexist with modest net profitability, elevated leverage, and conflicting distress and quality screens; renewed AUSTEDO pressure or weak profit conversion would make that debt burden harder to reduce.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.94 sits in the distress zone (elevated bankruptcy risk).
- Rich valuation — a P/E of 94.71 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Teva Pharmaceutical Industries (TEVA)?
Short answer · as of
Current published price targets run low $44.00 · high $54.00 · consensus $48.22 · median $48.00 against a quoted price of $38.54 (as of Nov 19, 2026).
Research dated 2026-09-12.
At the upcoming earnings release, track whether revenue again clears expectations and whether that strength reaches operating profit, reported earnings, and operating cash flow. Gross-margin delivery and the promised normalization of operating expenses would provide direct evidence that transformation savings are reaching the income statement.
AUSTEDO deserves separate attention because management expects purchasing and pricing pressure tied to IRA implementation. Longer-range consensus estimates assume rising revenue and earnings, so sustained product growth alongside steadier cash conversion would support that path; another disconnect between sales and profit would challenge it.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Teva Pharmaceutical Industries compare with its peers?
Short answer
Teva Pharmaceutical Industries's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Teva combines the manufacturing breadth of a global generics supplier with named specialty franchises, biopharmaceutical products, active pharmaceutical ingredients, and collaborative drug development. Its dosage forms range from tablets and injectables to inhaled, transdermal, and topical products.
Product sales dominate the reporting mix, while distribution and licensing add smaller revenue streams. That makes Teva different from a pure royalty biotechnology company and from a narrowly focused branded drugmaker: manufacturing scale and commercial breadth matter alongside the performance of individual specialty medicines.
| Company | Price | Market value | Score |
|---|---|---|---|
| $102.00 Nov 18, 2026 | $6.67B | 96 5-pillar Nov 18, 2026 | |
| $80.19 Nov 19, 2026 | $29.9B | 93 5-pillar Nov 18, 2026 | |
| $85.57 Nov 18, 2026 | $34.8B | 87 5-pillar Nov 18, 2026 | |
| $29.27 Nov 19, 2026 | $28.6B | 78 5-pillar Nov 18, 2026 | |
| $14.85 Nov 19, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| $9.08 Nov 18, 2026 | $39.8B | 75 5-pillar Nov 18, 2026 | |
| $28.35 Nov 19, 2026 | $5.89B | 74 5-pillar Nov 18, 2026 | |
| $21.27 Nov 18, 2026 | $68.0B | 73 5-pillar Nov 18, 2026 | |
| $21.88 Nov 18, 2026 | $7.62B | 66 5-pillar Nov 18, 2026 | |
| $456.48 Nov 19, 2026 | $89.7B | 60 5-pillar Nov 18, 2026 | |
| Teva Pharmaceutical Industries (TEVA) — this page | $38.54 | $45.0B | 57 |
| $251.41 Nov 18, 2026 | $37.2B | 37 5-pillar Nov 18, 2026 | |
| $289.50 Nov 18, 2026 | $42.0B | 36 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $44.00 – $54.00
- Consensus target
- $48.22
- Median target
- $48.00
Consensus record · Captured .
Measured against a quoted price of $38.54 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 79
- Identified insiders
- 21
- Purchases
- 0
- Sales
- 24
- Other transactions
- 55
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held TEVA in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.17% | $38.92M | New position |
| ARK Invest | Cathie Wood | Q3 2026 | 0.02% | $2.74M | New position |
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0% | $0 | Sold out (was $21.18M) |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Teva Pharmaceutical Industries (TEVA)?
Common Questions About TEVA (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why could AUSTEDO weaken even if Teva’s wider portfolio grows?
Management expects purchasing patterns and the pricing environment ahead of IRA implementation to weigh on AUSTEDO. The broader test is whether other product sales and transformation savings can offset that pressure.
Why did Teva’s profit fall while revenue rose?
The latest period paired higher revenue and gross profit with higher research and selling costs, while operating profit collapsed and the net result turned negative. Sales growth therefore failed to translate into reported profit.
What does Teva sell beyond generic medicines?
Teva sells specialty and biopharmaceutical treatments including AUSTEDO, AJOVY, and Copaxone, respiratory and oncology medicines, and active pharmaceutical ingredients. It also develops long-acting injectable formulations through its MedinCell collaboration.
How does MedinCell fit into Teva’s portfolio?
The collaboration extends Teva’s development portfolio into long-acting injectable formulations, including a risperidone suspension for schizophrenia. It complements the company’s established generics and specialty products rather than replacing either business.
What is the TEVA stock price today?
The last price recorded for Teva Pharmaceutical Industries Limited (TEVA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TEVA price target?
The analyst consensus price target for Teva Pharmaceutical Industries Limited (TEVA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold TEVA
Funds in our ETF coverage that list TEVA among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| VanEck Israel ETF (ISRA) | 11.43% | |
| WCMI ETF | 3.30% |